Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary obtains the drug registration certificate for Bisoprolol Amlodipine tablets.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (referred to as Rongsheng), has received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets issued by the National Medical Products Administration. Bisoprolol Amlodipine Tablets, as an alternative therapy for hypertension, are suitable for patients who are currently taking the same dose of a single drug and have good blood pressure control while on compound preparations.